Cyclo Therapeutics Equity Warrants Exp 11 Dec 2025 *W EXP 12/11/2025Change company Symbol lookupSelect an option...CYTHW Cyclo Therapeutics Equity Warrants Exp 11 Dec 2025 *W EXP 12/11/2025MSFT Microsoft CorpOMGA Omega Therapeutics IncINBS Intelligent Bio Solutions IncPAYX Paychex IncPYR Pyrogenesis Canada IncPM Philip Morris International IncGWAV Greenwave Technology Solutions IncSLNO Soleno Therapeutics IncVRPX Virpax Pharmaceuticals IncGo
Cyclo Therapeutics, Inc. is a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company’s lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is a treatment for Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. It is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. Its product lines include Trappsol and Aquaplex. The Company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The Company sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors.
|
|
|
|
| |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.